UPDATE: Dawson James Initiates Celsion at Market Outperform on Phase III Catalyst

Loading...
Loading...
Dawson James initiated coverage on Celsion
CLSN
with a Market Outperform rating and a $9 price target. Dawson James said, "In our opinion, should the HEAT trial read out positively as we expect, it will not only be viewed by investors as a validation of the market opportunity for ThermoDox, but for the entire clinical development strategy across multiple tumor types with significant commercial potential. It is worth noting that CLSN owns all the worldwide rights to ThermoDox with the exception of Japan. A future corporate collaboration could be yet another material value-driver in a reasonable (12-18 month) investment time horizon." Celsion closed at $6.66 on Monday.
Posted In: Analyst ColorInitiationIntraday UpdateAnalyst RatingsDawson James
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...